189464AC4
Clovis Oncology Inc
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company based in Boulder, Colorado, that developed cancer drugs, most notably Rubraca (rucaparib), a PARP inhibitor pill for people with ovarian and prostate cancers. Founded in 2009 by Patrick Mahaffy and other former executives of Pharmion Corporation, it took its name from the Mahaffy Cache, ancient Clovis-era stone tools unearthed in Mahaffy's own front yard. After entering bankruptcy proceedings in 2022, its drug assets were sold to other pharmaceutical companies.
CONVERTIBLEUnderlying: CLVSEURCUSIP: 189464AC4HealthcareUS1 derivative reporter
1.25% Convertible Senior Notes due May 1, 2025
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
